What is Glimepiride (Amaryl)?
It is a hypoglycaemic agent belonging to the second generation sulfonylureas. It appears to lower blood glucose by stimulating insulin release from beta cells in the pancreatic islets possibly due to increased intracellular cAMP. Glimepiride is a medium-to-long acting sulfonylurea anti-diabetic drug. It is marketed as Amaryl by Sanofi-Aventis and Glyree by Ipca. Glimepiride is the first third-generation sulfonylurea, and is very potent. This drug is commonly sold as Brand Name Amaryl.
Indication/Contraindication for use of Glimepiride (Amaryl)
- Pregnancy and lactation.
- Noninsulin dependent diabetes.
Side Effects of Glimepiride (Amaryl)
Hypoglycaemia, temporary visual impairment, gastrointestinal disturbences.
Dosage and Prescribing Information for Glimepiride (Amaryl)
Initially 1 mg once daily is given. Based on regular blood sugar monitoring, titration in dose is carried out step wise at intervals of 1 to 2 weeks.
Drug Interactions of Glimepiride (Amaryl)
Insulin and other oral antidiabetics, ACE inhibitors, allopurinol anabolic steroids and male sex hormones, chloramphenicol, coumarin derivatives, cyclophosphamide, disopyramide, fenfluramine, fluoxetine, guanethidine, if osfamide, MAO inhibitors, miconazole, phenylbutazone, oxyphenbutazone, probenecid causes potentiation of hypoglycaemic effect.
Precautions while prescribing Glimepiride (Amaryl)
Not to operate machinery or vehicle.